1
|
Ellins EA, Wareham K, Harris DE, Hanney M, Akbari A, Gilmore M, Barry JP, Phillips CJ, Gravenor MB, Halcox JP. Incident atrial fibrillation and adverse clinical outcomes during extended follow-up of participants recruited to the remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study. Eur Heart J Open 2023; 3:oead047. [PMID: 37205320 PMCID: PMC10187779 DOI: 10.1093/ehjopen/oead047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Revised: 04/25/2023] [Accepted: 05/02/2023] [Indexed: 05/21/2023]
Abstract
Aims Atrial fibrillation (AF) is an important risk factor for stroke, which is commonly asymptomatic, particularly in older patients, and often undetected until cardiovascular events occur. Development of novel technology has helped to improve detection of AF. However, the longer-term benefit of systematic electrocardiogram (ECG) screening on cardiovascular outcomes is unclear. Methods and results In the original REHEARSE-AF study, patients were randomized to twice-weekly portable electrocardiogram (iECG) assessment or routine care. After discontinuing the trial portable iECG assessment, electronic health record data sources provided longer-term follow-up analysis. Cox regression was used to provide unadjusted and adjusted hazard ratios (HR) [95% confidence intervals (CI)] for clinical diagnosis, events, and anticoagulant prescriptions during the follow-up period. Over the median 4.2-year follow-up, although a greater number of patients were diagnosed with AF in the original iECG group (43 vs. 31), this was not significant (HR 1.37, 95% CI 0.86-2.19). No differences were seen in the number of strokes/systemic embolisms or deaths between the two groups (HR 0.92, 95% CI 0.54-1.54; HR 1.07, 95% CI 0.66-1.73). Findings were similar when restricted to those with CHADS-VASc ≥ 4. Conclusion A 1-year period of home-based, twice-weekly screening for AF increased diagnoses of AF for the screening period but did not lead to increased diagnoses of AF or a reduction in cardiovascular-related events or all-cause death over a median of 4.2 years, even in those at highest risk of AF. These results suggest that benefits of regular ECG screening over a 1-year period are not maintained after cessation of the screening protocol.
Collapse
Affiliation(s)
| | - Kathie Wareham
- Faculty of Medicine, Health & Life Science, Swansea University Medical School, Singleton, Swansea SA2 8PP, UK
| | - Daniel E Harris
- Population Data Science, Swansea University Medical School, Faculty of Medicine, Health & Life Science, Swansea University, Singleton Park, Swansea, SA2 8PP, UK
- Titech Institute, Hywel Dda University Health Board, Llanelli, UK
| | - Matthew Hanney
- Faculty of Medicine, Health & Life Science, Swansea University Medical School, Singleton, Swansea SA2 8PP, UK
| | - Ashley Akbari
- Population Data Science, Swansea University Medical School, Faculty of Medicine, Health & Life Science, Swansea University, Singleton Park, Swansea, SA2 8PP, UK
| | - Mark Gilmore
- Cardiology, Princess of Wales Hospital, Bridgend, UK
| | - James P Barry
- Regional Cardiac Centre, Morriston Hospital, Swansea, UK
| | - Ceri J Phillips
- Swansea University College of Health and Human Sciences, Faculty of Medicine, Health & Life Science, Swansea University, Swansea, UK
| | - Michael B Gravenor
- Population Data Science, Swansea University Medical School, Faculty of Medicine, Health & Life Science, Swansea University, Singleton Park, Swansea, SA2 8PP, UK
| | - Julian P Halcox
- Population Data Science, Swansea University Medical School, Faculty of Medicine, Health & Life Science, Swansea University, Singleton Park, Swansea, SA2 8PP, UK
| |
Collapse
|